Journal
DRUG RESISTANCE UPDATES
Volume 4, Issue 1, Pages 50-65Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1054/drup.2000.0177
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI44199] Funding Source: Medline
Ask authors/readers for more resources
Glycolysis is perceived as a promising target for new drugs against parasitic trypanosomatid protozoa because this pathway plays an essential role in their ATP supply, Trypanosomatid glycolysis is unique in that it is compartmentalized, and many of its enzymes display unique structural and kinetic features. Structure- and catalytic mechanism-based approaches are applied to design compounds that inhibit the glycolytic enzymes of the parasites without affecting the corresponding proteins of the human host. For some trypanosomatid enzymes, potent and selective inhibitors have already been developed that affect only the growth of cultured trypanosomatids, and not mammalian cells. (C) 2001 Harcourt Publishers Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available